

In the claims:

The listing of claims below will replace all prior versions, and listings, of claims in the application.

1. (currently amended) A method of identifying a test compound useful for the treatment of an impaired maximum gastric accommodation capacity, wherein the method comprises:

administering a test compound to a non-human animal identified to have an impaired maximum gastric accommodation capacity;

measuring the gastric accommodation during a ramp phase and during a tonic phase and determining from these measurements the maximum gastric accommodation capacity in the animal following administration of the compound, wherein the determination is made after a ramp phase; and

comparing the maximum gastric accommodation capacity of the animal before and after administration of the test compound, wherein an increase in the accommodation capacity in the animal following administration of the compound is indicative that the compound is useful for the treatment of impaired maximum gastric accommodation capacity.

2. (original) The method of claim 1, wherein the non-human animal is a rat or a dog.

3. (previously presented) The method of claim 2, wherein the rat is a Wistar Kyoto rat.

4. (original) The method of claim 1, wherein the compound is a nitrogen oxide synthase (NOS) inhibitor, a 5HT-3 agonist, a 5HT-4 antagonist, an alpha-2 agonist, a glucagon or a cholinergic agonist or antagonist.

5. (original) The method of claim 1 wherein the compound is administered orally.

6-13. (cancelled)